Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Clinical trial NCT02208843 · COMPLETED

Trial details

NCT number: NCT02208843
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2014-10-02
Primary completion: 2017-05-17
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.